Zaniolo, Orietta, et al. “Budget Impact of Rosiglitazone in Type 2 Diabetes”. Farmeconomia. Health Economics and Therapeutic Pathways, vol. 8, no. 1, Mar. 2007, pp. 15-26, doi:10.7175/fe.v8i1.252.